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DOI 10.1186/s12882-015-0212-4RESEARCH ARTICLE Open AccessThe role of natriuretic peptides in volume
assessment and mortality prediction in
Haemodialysis patients
Murugan Sivalingam, Enric Vilar, Suresh Mathavakkannan and Ken Farrington*Abstract
Background: Maintaining optimal fluid balance is essential in haemodialysis (HD) patients but clinical evaluation
remains problematic. Other technologies such as bioimpedance are emerging as valuable adjuncts. This study was
undertaken to explore the potential utility of the natriuretic peptides – atrial natriuretic peptide (ANP) and B-type
natriuretic peptide (BNP) in the assessment of fluid status and cardiovascular risk in this setting.
Methods: This was a cross-sectional study carried out in an unselected cohort of 170 prevalent HD patients.
Volume status was assessed by clinical parameters – the presence or absence of peripheral oedema, raised jugular
venous pressure and basal lung crepitations; by extracellular fluid volume (ECFV) status determined by whole body
bioimpedance; and by serum levels of BNP and ANP (pre- and post –dialysis). The relationships of ANP and BNP
levels to clinical and bioimpedance parameters of volume status was determined. Patients were followed up for
5 years to assess the relationship of natriuretic peptide levels to mortality.
Results: Bioimpedance estimates of ECFV expansion (>105 % of ideal ECFV) was present in 52 % of patients pre-dialysis.
A significant proportion (21 %) of pre-dialysis patients had a depleted ECFV (<95 % of ideal ECFV) pre-dialysis. The
situation was reversed post-dialysis. A raised JVP >3 cm was the most reliable clinical sign of ECFV expansion inferred
from bioimpedance measurements and natriuretic peptide levels. The vast majority of patients with this sign also had
lung crepitations or peripheral oedema or both. BNP was a stronger predictor of ECFV expansion than either pre- or
post-dialysis ANP. BNP was also a stronger predictor of five-year survival.
Conclusion: Serum levels of BNP have a strong relationship to both volume status and survival in HD patients. We found
no clear role for measurement of ANP, though changes in blood levels may be a sensitive indicator of acute changes in
volume status. Whether monitoring levels of these peptides has a role in the management of volume status and
cardiovascular risk requires further study.Background
The maintenance of optimum fluid balance in patients
on haemodialysis (HD) is a key therapeutic goal, and
plays a major role in determining morbidity and mortal-
ity. Clinical assessment remains the main arbiter of vol-
ume status though relatively insensitive. Other measures
may be helpful, the most well explored of these being
bioimpedance methodologies. Blood levels of a bio-
marker of fluid status would be of huge benefit. Natri-
uretic peptide are candidate biomarkers which have
shown promise in other settings, but their role in this* Correspondence: ken.farrington@nhs.net
Renal Unit, Lister Hospital, Stevenage, Herts SG1 4AB, UK
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compared the performance of plasma B-type Natriuretic
Peptide (BNP) levels, clinical assessment, and bioimpe-
dance methods [1–4] None to our knowledge have in-
cluded Atrial Natriuretic Peptide (ANP) in these
comparisons.
Natriuretic peptides play a major role in salt and water
homeostasis, protecting the cardiovascular system from
the effects of volume overload. ANP (28 amino acids)
and BNP (32 amino acids) share a common 17-amino-
acid ring structure. Both peptides are released primarily
from the heart and act in various tissues inducing vaso-
dilatation, natriuresis and diuresis [5]. ANP is predomin-
antly synthesised in the atria and BNP in the ventricles,ticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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pathological conditions [6]. ANP is stored in atrial gran-
ules and released even with minor increases in volume
whilst BNP, which only has minimal storage in granules,
is synthesised and secreted in bursts [7]. ANP is stored
as pre-proANP, which is then cleaved to proANP and
then finally to the inactive NT proANP (1–98) and the
biologically active ANP (99–126). Synthesis of pre-
proBNP in the ventricle is initiated by wall stress due to
either volume expansion or pressure overload [8]. Pre-
proBNP is cleaved initially to proBNP (1–108) and then
to the biologically active BNP (1–32) and the inactive
amino-terminal fragment (NT proBNP). The biological
actions of natriuretic peptides are mediated by binding
with specific membrane bound receptors and activation
of the guanyl cyclase system [9]. Both peptides are inac-
tivated by enzymatic degradation by neutral endopeptid-
ase and lysosomal degradation after uptake by the
clearance receptor [10]. ANP binds to the clearance re-
ceptor with greater affinity than BNP and so has a
shorter half-life. The half-life of ANP is 2–3 min whilst
that of BNP is around ten-fold greater [11].
Both ANP and BNP have been investigated as markers
of hydration in dialysis patients. Mean ANP levels are
markedly increased in dialysis patients, decrease with
ultrafiltration, but remain constant during isovolaemic
HD suggesting that reduced synthesis in response to de-
creasing circulating volume is their main determinant
[12]. Elevated ANP levels post-dialysis are associated
with fluid overload. Consistent weight reduction was
followed by a decrease of ANP levels but the levels
remained high compared with levels normal subjects.
Other studies have reported similar findings [13–17].
Blood levels of BNP also reflect volume status in dialy-
sis patients [4, 18], in addition they are strongly associ-
ated with left ventricular dysfunction [19]. There is data
though to suggest that NT proBNP levels may be more
reflective of volume overload than of cardiac dysfunction
[20]. BNP has been shown to be more closely correlated
with left ventricular mass index and ejection fraction
than ANP and in this study only BNP was an independ-
ent predictor of death [21]. BNP levels decrease signifi-
cantly during high-flux HD, dialyser clearance being the
major contributant [22, 23]. Volume change appears to
play a much smaller role – suggesting a relative insensi-
tivity of BNP secretion to acute volume change [22, 23].
In keeping with this is the lack of change of BNP levels
during low-flux HD in spite of a reduction in volume
status due to ultrafiltration [18]. In the same study ANP
levels fell significantly during the dialysis session, sug-
gesting ANP to be a better marker of acute volume
change than BNP
In summary comparative studies of ANP and BNP
have suggested that in this setting ANP may be thebetter marker of volume status and BNP might the bet-
ter marker of cardiac dysfunction. Hence we sought to
assess the clinical utility of pre-dialysis ANP levels and
changes in these levels during a dialysis session as
markers of volume status assessed clinically and by
bioimpedance. Predialysis BNP levels were taken, pri-
marily as an indication of cardiac functional status. We
also aimed to investigate the association between these
biomarkers and survival.
Methods
Study population
Patients undergoing outpatient HD under the auspices
of the Lister Renal Unit, Stevenage UK were supplied
with details of the study and subsequently approached to
take part. There were no exclusion criteria except the in-
ability to give informed consent. A non-selective recruit-
ment strategy was pursued in order to ensure that the
findings of the study were applicable to a typical dialysis
population. The study was approved by the Hertford-
shire Ethical Review Committee.
Haemodialysis programme
All patients received thrice-weekly HD using high-flux
membranes, predominantly polysulphone. Water qual-
ity was regularly monitored to ensured tight bacterio-
logical standards [<0.1 cfl/ml and <0.03 EU/ml].
Around 50 % of patients were treated by on-line
post-dilution haemodiafiltration (HDF). Dialysis was
individualised and prescribed and monitored accord-
ing to a target two-pool total Kt/V of 1.2 per session,
composed of dialysis component (Kt/Vdialysis) plus a
component derived from residual renal urea clearance
(Kt/Vrenal). To achieve this pre- and post-dialysis
blood urea levels and interdialytic urine collections
were carried out monthly. Dialysis fluid contained so-
dium (138 mmol/L); potassium (2 mmol/L); calcium
(1.25 mmol/L); magnesium (0.5 mmol/L); chloride
(108.5 mmol/L); bicarbonate (35 mmol/L) and glucose
(5.5 mmol/L). Dialysate temperature was 36 °C.
Protocol
1. Informed written consent obtained.
2. Patients were studied during a single dialysis session
in mid-2008.
3. Predialysis clinical examination was carried out
4. Extracellular fluid volumes were measured using
whole-body bioimpedance at the beginning of dialy-
sis session.
5. Two samples for serum ANP was taken – one at the
start (pre dialysis) and one at the end of the dialysis
(post dialysis). A single sample was taken for serum
BNP was also taken pre dialysis.
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haematological data were retrieved from case-notes
and electronic records
7. Patients were followed up through their electronic
patient record to death on dialysis or for 5 years.
Follow up was discontinued after transplantation or
transfer to another dialysis centre and survival data
censored at the date of transplantation or transfer.Clinical examination
A detailed clinical examination was carried out by one
of two experienced renal registrars, to assess each pa-
tient’s volume status.
Note was made of the presence or absence of:
 an elevated JVP – measured with respect to the
sternal angle
 auscultatory crackles at the lung bases
 peripheral oedema.Routine data collection
The following data was collected on all patients
1. Demographic parameters including age, sex, dialysis
vintage
2. Clinical parameters including primary renal
disease, the presence of diabetes, and the
presence of cardiac disease and other
comorbidities. The presence of cardiac disease
was inferred by a history of Myocardial
Infarction, invasive coronary intervention, angina,
chronic atrial fibrillation, cardiomyopathy, or
valvular heart disease. A record of anti-
hypertensive drug therapy was recorded The
Charlson Comorbidity Index (CCI) was also cal-
culated [24].
3. Details of dialysis session, including pre- and post-
dialysis body weight and blood pressure, ultrafiltra-
tion volume (UFV) and ultrafiltration rate (UFR),
and duration of dialysis session (Td).
4. Data relating to the immediately preceding monthly
monitoring round including sessional Kt/V, residual
renal function (KRU), serum albumin, and C-
reactive protein (CRP)Biochemical measurements
ANP
αANP was measured by ELIZA assay (Peninsula La-
boratories, San Carlos, CA, USA). Blood samples were
taken in chilled EDTA tubes, centrifuged at 5 °C,
plasma separated and stored at –20C. The normal
concentrations vary between 15 and 40 pg/ml.BNP
BNP 77–108 (carboxyl terminal peptide or BNP 32) was
measured using a Triage BNP Assay kit (Biomed diag-
nostics incorporated, San Diego, CA). This kit deploys
an immunofluorescence assay using a 0.5 ml EDTA
blood sample with normal range <100 pg/ml.
Whole body bioimpedance
Whole body bioimpedance measurements were carried
out using the Xitron 4200. The device uses the Cole
model to derive the resistance values and has the soft-
ware algorithm built-in to calculate the respective fluid
volumes. We derived estimates of excess ECF using the
method described by Chamney [25] which utilises the
slope between ECF volume (bioimpedance) and body
weight at normovolaemia. For males the slope was
0.239 L/kg and for females 0.214 L/kg. Using these
values “ideal ECF” was determined and Excess ECF as
the difference between measured ECF and “ideal ECF”.
Statistical analysis
All data with a normal distribution are presented as
mean ± sd. Non-normally distributed data is presented
as median (Interquartile range). The distributions of
ANP, BNP, KRU and CRP values were not normal. The
Students “t” test, ANOVA, the Mann–Whitney test, and
the Kruskal-Wallis test were used as appropriate to ana-
lyse the differences between the groups. A p-value of
<0.05 was assumed to indicate statistical significance.
The diagnostic utility of ANP and BNP in predicting vol-
ume overload and survival was analysed using the Re-
ceiver Operating Characteristics curve (ROC) analysis.
Area under the curve (AUC) was compared for each of
the peptide measurements. The predictors of volume
overload (defined as ECFV >105 % of ideal ECF as deter-
mined by bioimpedance [25]) were determined in
stepped logistic regression analysis (Backwards LR). The
predictors for survival were assessed using Cox Propor-
tional Hazards regression analysis controlled for age,
sex, ethnicity, pre-dialysis weight, residual urea clear-
ance > 1 ml/min, CCI, serum albumin, and elevated CRP
(>5 mg/l). Values of ANP and BNP were logarithmically
transformed for use in these regression analyses. SPSS
version 19 was used for all these analyses.
Results
One hundred and seventy patients were studied
(Table 1). Mean age was 66 ± 13 years. Sixty-eight per-
cent of the patients were male. There were no significant
gender differences in pre dialysis ANP and BNP but
there was a trend toward post dialysis ANP being higher
in men compared to women (86.8 [IQR 116] vs. 64.5
[IQR 74] pg/ml, p = 0.053). Forty-four (26 %) had dia-
betes. Median RRT vintage was 42 [48 IQR] months.
Table 1 Demographic, clinical, biochemical, and bioimpedance
characteristics in 170 dialysis patients
Demographic and Clinical Characteristics
Number 170
Age (Years) 66 ± 13
Gender (% Male) 68
Ethnicity (%White) 84
Predialysis weight (kg) 73.7 ± 15.4
Diabetes (%) 26
Cardiac Disease (%) 45
Cancer (%) 13
Charlson Comorbidity Index 5.7 ± 2.1
RRT Vintage (months) 42 [48]
Biochemical Parameters
Serum Sodium (mmol/l) 136.9 ± 3.2
Serum albumin (g/l) 35.5 ± 4.6
Haemoglobin level (g/l) 11.6 ± 1.4
High CRP >5 mg/l (%) 48
KRU (ml/min) 0.3 [1.5]
KRU > 1 ml/min (%) 33
Dialysis Parameters
Dialysis session time (minutes) 184 ± 30
Sessional Kt/V 1.29 ± 0.21
Ultrafiltration volume (litres) 1.7 [1.4]
Clinical Assessment of Volume
Pre-dialysis Systolic BP (mmHg) 151 ± 25
Pre-dialysis Diastolic BP (mm Hg) 79 ± 15
Post-dialysis Systolic BP (mmHg) 137 ± 26
Antihypertensive medication (%) 74
Oedema (%) 37
JVP > 3 cm (%) 38
Basal Crepitations (%) 54
Bioimpedance Parameters
ECFV (l) 17.91 ± 3.98
Ideal ECFV (Chamney) 17.09 ± 4.03
Excess ECFV 0.82 ± 2.46
Natriuretic Peptide levels
Pre-dialysis ANP (pmol/l) 169 [208]
Post-dialysis ANP (pmol/l) 79 [106]
Pre-dialysis BNP (pmol/l) 325 [1206]
RRT renal replacement therapy, CRP C reactive protein, KRU residual urea
clearance (ml/min). ECFV extracellular fluid volume, BP blood pressure
Fig. 1 Mean % ECF excess based on bioimpedance estimates.
Euvolaemic = ideal ECF [Chamney (25) +/− 5 %. Hypovolaemic =
ECF < 95 % ideal. Hypervolaemic = ECF > 105 % ideal. Numbers in
these categories indicate the percentage of the study population
with ECF values in that category
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Mean sessional Kt/V was 1.29 ± 0.21, with a mean dur-
ation (Td) of 184 ± 30 mins. Mean pre-dialysis weight
was 73.7 ± 15.4 kg.Clinical signs of fluid overload
Mean ultrafiltration volume (UFV) was 1.7 [1.4 IQR] li-
tres per session (Table 1). Mean systolic BP was 151 ± 25
(pre-dialysis) and 137 ± 26 mmHg (post-dialysis). Corre-
sponding diastolic pressures were 79 ± 15 and 73 ±
13 mmHg respectively. Sixty-three patients (37 %) were
judged as having clinical signs of oedema, 65 (38 %) as
having a raised JVP (>3 cm) and as having 92 (54 %)
basal crepitations on lung auscultation (Table 1). Thirty-
three patients (19 %) had all three of these signs, 34
(20 %) had two, 52 (31 %) had one, and only 51 (30 %)
had none.Extracellular fluid volume estimates by bioimpedance
Mean measured extracellular fluid volume (ECFV) pre-
dialysis was 17.91 ± 3.98 l. Applying the Chamney equa-
tion the mean “ideal” ECFV was 17.09 ± 4.03 l (Table 1).
Hence the mean excess ECFV (ECFVexcess) was 0.82 ±
2.46 l. On this basis 45 patients (27 %) were within 5 %
of their “ideal ECFV”(Euvolaemic), 36 patients (21 %)
were more than 5 % below their “ideal ECF”(Hypovolae-
mic) and 89 patients (52 %) more than 5 % above it
(Hypervolaemic) (Fig. 1).Natriuretic peptide levels
The median ANP levels were pre-dialysis 169 (IQR 208),
and post-dialysis 79 (IQR 106) pg/ml. The median BNP
level was 325 (IQR 1206) pg/ml (Table 1). Both pre- and
post-dialysis ANP levels correlated significantly with
BNP levels (rho = 0.760 and 0.688 respectively; p < 0.001
in both cases).
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Physical signs
Oedema Patients with oedema were older and heavier
than those without (Table 2). They also had higher sys-
tolic pressures pre-dialysis, lower serum albumin levels
and a higher ECFV. There were no other significant dif-
ferences, in particular no differences in natriuretic pep-
tide levels.
Elevated Jugular Venous Pressure (JVP) Those with
elevated JVP levels > 3 cm tended to have less residual
renal function than those without (Table 2). They also
had higher pre-dialysis blood pressure levels – both sys-
tolic and diastolic, higher ECFV levels, and a higher pro-
portion had a significantly expanded ECFV (Table 2).
Levels of all natriuretic peptides were significantly higher
in those with elevated JVP of this degree than in those
without this sign.Table 2 Comparison of Demographic, Clinical, Biochemical and Bioi
3 cm, and lung crepitations
Oedema p-value JVP >
Yes No Yes
Number 62 108 65
Age (years) 69 ± 12 64 ± 14 0.021 66 ±
Gender (%male) 68 68 NS 74
Ethnicity (%white) 89 82 NS 88
Pre-dialysis weight (kg) 77.9 ± 18.2 71.2 ± 13.1 0.020 75.3
KRU (ml/min) 0.38 (1.33) 0.26 (1.64) NS 0.01
Cardiac History (%) 50 43 NS 46
Charlson Comorbidity Index 6.1 ± 1.8 5.5 ± 2.3 0.053 5.4 ±
Kt/V 1.29 ± 0.18 1.29 ± 0.23 NS 1.27
Serum sodium (mmole/l) 137.1 ± 3.4 136.5 ± 3.2 NS 137.2
Albumin (g/l) 34.6 ± 4.8 36.1 ± 4.4 0.043 35.7
High CRP(>5 mg/l) 55 44 NS 54
Ultrafiltration Volume (l) 1.84 ± 1.10 1.63 ± 1.03 NS 2.05
Systolic-pre (mmHg) 157 ± 25 148 ± 25 0.018 161 ±
Diastolic-pre (mmHg) 80 ± 15 79 ± 15 NS 84 ±
Systolic-post (mmHg) 140 ± 26 135 ± 26 NS 140 ±
Diastolic-post (mmHg) 73 ± 13 74 ± 13 NS 75 ±
Antihypertensive drugs (%) 76 72 NS 80
ECFV (l) 19.0 ± 4.5 17.3 ± 3.5 0.014 19.1
ECFV Excess (l) 0.87 ± 3.28 0.79 ± 1.84 NS 1.57
ECFV Excess (% Ideal ECFV) 6.68 ± 16.72 5.44 ± 11.69 NS 10.08
Excess ECFV (>5 %) 57 49 NS 68
ANP-pre (pmol/l) 185 (268) 160 (199) NS 201 (
ANP-post (pmol/l) 86 (123) 73 (99) NS 101 (
BNP (pmol/l) 401 (1157) 286 (1245) NS 592 (
KRU urea clearance, CRP serum C-Reactive Protein, ECFV extracellular fluid volume, ALung crepitations Patients with lung crepitations were
heavier than those without and also had higher ECFV
levels, though minimal evidence of ECFV expansion.
Blood pressure was higher especially pre-dialysis. Pre-
dialysis ANP levels were also higher, though neither
post-dialysis ANP nor BNP levels were significantly dif-
ferent between those with and those without this sign
(Table 2).
The most powerful predictor of expanded ECFV was
elevated JVP >3 cm. In fact of the 65 patients assessed
as having this sign, 59 (91 %) also had lung crepitations
or oedema or both.
Bioimpedance measures – excess ECF
The associations with bioimpedance-derived assessments
of volume status – hypovolaemia, euvolaemia, and
hypervolaemia – as defined above are shown in Table 3.
The majority of patients (52 %) were identified as hyper-
volaemic, having an ECFV > 5 % above the ideal. Thesempedance parameters in patients with oedema, raised JVP >
3 cm p-value Crepitations p-value
No Yes No
105 92 78
12 67 ± 13 NS 66 ± 13 66 ± 13 NS
64 NS 74 60 0.058
82 NS 87 80 NS
± 15.5 72.6 ± 15.4 NS 77.0 ± 16.5 69.8 ± 13.1 0.002
(1.06) 0.35 (1.82) 0.07 0.10 (1.22) 0.30 (1.83) NS
45 NS 47 44 NS
2.0 5.9 ± 2.2 NS 5.7 ± 2.1 5.7 ± 2.1 NS
± 0.16 1.30 ± 0.24 NS 1.26 ± 0.17 1.32 ± 0.24 0.066
± 3.0 136.7 ± 3.3 NS 136.9 ± 3.0 136.9 ± 3.5 NS
± 4.3 35.3 ± 4.7 NS 36.0 ± 3.9 35.0 ± 5.3 NS
44 NS 52 45 NS
± 1.12 1.50 ± 1.00 0.001 1.97 ± 1.03 1.40 ± 1.01 <0.001
26 145 ± 22 <0.001 158 ± 25 144 ± 23 <0.001
16 76 ± 13 0.001 82 ± 15 76 ± 14 0.008
29 134 ± 23 NS 140 ± 27 133 ± 24 NS
13 72 ± 12 NS 75 ± 13 71 ± 12 NS
70 NS 75 72 NS
± 3.9 17.1 ± 3.8 0.001 19.1 ± 4.1 16.5 ± 3.3 <0.001
± 2.42 0.36 ± 2.38 0.002 1.12 ± 2.38 0.47 ± 2.52 0.085
± 13.49 3.29 ± 13.24 0.002 7.37 ± 13.3 4.14 ± 14.03 NS
42 0.002 58 46 NS
276) 149 (192) 0.023 197 (246) 147 (200) 0.042
177) 72 (83) 0.038 88 (109) 70 (88) NS
1553) 281 (677) 0.014 410 (1369) 286 (675) NS
NP Atrial Natriuretic Peptide, BNP B-type Natriuretic peptide
Table 3 Comparison of characteristic of hypovolaemic, euvolaemic and hypervolaemic groups
Hypovolaemic<95 % ideal ECF Euvolaemic Ideal ECF ± 5 % Hypervolaemic>105 % ideal ECF p-value
Number 36 45 89
Demographic, clinical & laboratory factors
Age (years) 63 ± 12 64 ± 14 c68 ± 13 0.085
% Male 56 71 71 NS
% White d67 82 c92 0.002
Weight (kg) d82 ± 20 75 ± 13 a,c70 ± 13 <0.001
Dialysis Vintage (months) 30 (34) 44 (46) 44 (53) 0.079
Diabetes (%) 39 22 24 NS
Cardiac History (%) 50 49 42 NS
Charlson Comorbidity Index 5.5 ± 2.3 5.5 ± 2.2 5.9 ± 2.0 NS
Haemoglobin (g/l) 116 ± 11 121 ± 13 a,c114 (15) 0.023
Serum albumin (g/l) 35.4 ± 5.4 36.5 ± 3.5 35.1 ± 4.7 NS
CRP > 5 mg/l b58 31 a52 0.029
Serum sodium <136 mmol/l (%) d47 29 27 0.079
KRU (ml/min) d0.80 (2.66) 0.34 (1.77) c0.04 (0.93) 0.011
Kt/V 1.32 ± 0.24 1.32 ± 0.25 1.29 ± 0.21 NS
Clinical assessment of volume status
Post-dialysis systolic BP (mmHg) d127 ± 20 135 ± 26 c141 ± 27 0.016
Lung Crepitations (%) 42 53 60 NS
Elevated JVP (>3 cm) (%) d19 29 a,c51 0.002
Oedema (%) 42 24 41 NS
Natriuretic peptide levels
ANP (pre-dialysis) (pmole/l) 147 (138) 149 (211) c195 (274) 0.040
ANP (pre-dialysis) < 150 mmole/l (%) 53 53 a,c35 0.056
ANP (post-dialysis) (pmole/l) 62 (65) 62 (101) c97 (116) 0.079
ANP (post-dialysis) < 100 pmole/l (%) 78 64 c51 0.015
BNP (pmole/l) d228 (564) 268 (681) a,c495 (1349) 0.003
BNP < 100 pmole/l (%) 25 33 a,c6 <0.001
Ultrafiltration characteristics
Ultrafiltration volume (l) 1.35 (1.50) 1.70 (1.20) 1.80 (1.55) NS
Ultrafiltration rate (ml/kg/h) d6.2 ± 4.2 7.6 ± 4.3 c8.5 ± 5.1 0.046
The p-value refers to the significance of difference across the three groups by one-way ANOVA or the Kruskal Wallis test or Chi-square test as appropriate. a refers
to a significant difference between hypervolaemic and euvolaemic groups. b refers to significance difference between hypovolaemic and euvolaemic groups.
c refers to a significant difference between hypervolaemic group and the other two groups combined, d refers to a significant difference between hypovolaemic
group and the other two groups combined
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nicity. Residual kidney function was significantly lower
than in other groups. More had elevated CRP levels than
euvolaemics. Clinical signs of hypervolaemia were also
more pronounced. In particular post-dialysis systolic
pressure was higher, and a significantly higher propor-
tion had a raised JVP > 3 cm. UF rates were also higher.
In addition natriuretic peptide levels were generally
higher than in both other groups, especially BNP levels.
A small but significant minority (21 %) were hypovol-
aemic by the definition used (ECFV < 95 % of ideal).
More of these patients were Non-white. They wereheavier and had more residual kidney function than
other groups. Again, more had elevated CRP levels
than euvolaemics and a higher proportion had a
serum sodium level < 136 mmol/l. Post-dialysis systolic
pressure was lower than in other groups and fewer
had a raised JVP > 3 cm. Ultrafiltration rates were
lower. Generally natriuretic peptide levels were lower than
in the hypervolaemic group, but similar to euvolaemic
levels, though median BNP levels were slightly lower than
in euvolaemics.
The utility of plasma levels of natriuretic peptides in pre-
dicting hypervolaemia as indicated by a bioimpedance-
Sivalingam et al. BMC Nephrology  (2015) 16:218 Page 7 of 10determined ECFV > 5 % above the ideal is demonstrated in
the ROC curve in Fig. 2. Though BNP levels (AUC: 0.650:
p = 0.001) were better predictors of hypervolaemia
than pre- (AUC: 0.607: p = 0.017) or post-dialysis
ANP levels (AUC: 0.595: p = 0.035), a cutoff level of
100 pmoles/l provided good sensitivity (94 %) but poor
specificity (30 %). The utility of BNP in predicting
hypovolaemia (ROC curve not shown) was even poorer
with AUC for BNP of 0.616: p =0.037).
Regression models of determinants of hypervolaemia
(ECFV > 105 % of ideal as determined by bioimpedance)
are shown in Table 4. The baseline regression model
included terms for gender, ethnicity, residual kidney
function and pre-dialysis weight. The only clinical
parameters which improved this model were post-dialysis
blood pressure and elevated JVP > 3 cm. The only
natriuretic peptide parameters which improved the
model related to BNP, the most significant of which
was serum BNP >100 pmol/l. Nagelkerke R square of
the final model (Model C) was 0.435.
Post-dialysis fluid balance
Assuming that the UF volume removed during dialysis
results in an equivalent reduction of the ECFV, the Ex-
cess ECF – post-dialysis can be calculated by subtracting
the UFV volume from the Excess ECF – pre-dialysis.
The results of this are shown in Fig. 3. The Excess ECF
is expressed as a percentage of the ideal ECF in relation
to the volume groups as defined above. It can be seen
that post-dialysis the euvolaemic group is unchanged inFig. 2 ROC curve indicating the utility of plasma levels of natriuretic
peptides in predicting hypervolaemia as indicated by a
bioimpedance-determined ECFV > 5 % above ideal ECF. For
interpretation – see textsize at 28 %, and that the size of the hypervolaemic
group has reduced to 22 % at the expense of a major in-
crease in the size of the hypovolaemic group which has
risen to 50 %. This almost represents a mirror image of
the pre-dialysis situation.
Fluid overload and survival
Eighty-four patients (49 %) died, 32 (19 %) were trans-
planted and one (0.6 %) transferred out during the 5 year
follow-up. The association of natriuretic peptides and
survival was explored in a series of ROC curves (Fig. 4).
BNP (AUC: 0.719: p < 0.001) provided a better prediction
of 5 year mortality than pre- (AUC: 0.652: p = 0.001) or
post-dialysis ANP levels (AUC: 0.665: p <0.001). For
BNP a cut-off level of 100 pmole/l provided a high sensi-
tivity (93 %) but poor specificity (30 %). A series of Cox
Regression models were constructed (Table 5). The base-
line model included terms for age, sex, ethnicity,, predia-
lysis weight, residual kidney function (KRU > 1 ml/min),
CCI, Kt/V, serum albumin and raised CRP (>5 mg/l). In
separate models (Models 1, 2 and 3) terms for log trans-
formed pre-dialysis ANP, post-dialysis ANP and BNP
were added to the baseline model. In these models pre-
dialysis and post-dialysis ANP terms were of only mar-
ginal significance, unlike that for BNP the term for
which was highly significant. Furthermore neither log
pre-dialysis ANP nor log post-dialysis ANP was signifi-
cant when added to Model 3 whilst log BNP retained its
significance.
Discussion
Fluid overload is common in HD patients and is associ-
ated with significant morbidity including excess risk of
cardiovascular disease as well as mortality. Whilst clin-
ical assessment remains the cornerstone, bioimpedance
methods are increasingly used to supplement this. Sev-
eral studies have utilised bioimpedance to provide ob-
jective assessment of volume status in HD patients [1,
26–29] This study explored the potential for estimates
of blood levels of natriuretic peptide to provide add-
itional clinically useful information. It also examines
their role in predicting survival.
Bioimpedance analysis in this study revealed that
though the majority of patients (52 %) had excess ECF, a
significant proportion (21 %) were hypovolaemic. Clin-
ical signs associated with fluid overload were prevalent
in this group of patients – oedema (37 %), raised JVP >
3 cm (38 %) and basal crepitations (54 %). Elevated JVP
>3 cms was the most powerful clinical predictor of ex-
panded ECF volume, and the only independent clinical
predictor of expanded ECF volume in multivariate ana-
lysis. It is also pertinent that 91 % of the patients who
were found to have a raised JVP of this degree also had
lung crepitations or oedema or both.
Table 4 Models of the determinants of hypervolaemia (ECFV >105 % of ideal as determined by bioimpedance)
B S.E. Wald p-value Exp(B)
Model A: Baseline model (Nagelkerke R-square 0.272)
Female v Male −1.296 .476 7.409 .006 .274
Non-white v White −1.859 .603 9.495 .002 .156
Residual Urea Clearance >1 ml/min .678 .403 2.824 .093 1.969
Pre-dialysis weight (kg) -.062 .016 14.648 .000 .939
Age and Charlson Comorbidity index - not significant in Model A
Model B: Baseline model plus clinical factors (Nagelkerke R square 0.372)
Post-dialysis systolic > 160 mmHg 1.190 .585 4.143 .042 3.288
Elevated JVP >3 cm 1.377 .422 10.656 .001 3.964
Parameters relating to pre-dialysis BP, oedema and basal lung crepitations – not significant in model B
Model C: Baseline model plus clinical factors and natriuretic factors (Nagelkerke R square 0.435)
BNP > 100 pg/ml 1.851 .602 9.468 .002 6.366
Parameters related to pre- and post-dialysis ANP not significant in model C
Constant 2.675 1.420 3.547 .060 14.505
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ANP, post dialysis ANP as well as BNP. There were no
significant differences in the level of pre dialysis ANP
and BNP with regards to gender but men in the study
tended to have higher levels of post dialysis ANP. A
number of studies have reported that natriuretic peptide
levels are elevated in HD patients and it has been sug-
gested that factors such as fluid overload, left ventricular
dysfunction and impaired renal clearance contribute to
this [19, 22, 30–33]. Pre and post dialysis ANP levels
correlated strongly with each other as well as with BNP
which is unsurprising.
We found that BNP was a stronger predictor of fluid
overload than pre and post dialysis ANP. This was evi-
dent both in terms of its relationship with clinical
markers of volume status, particularly elevated JVPFig. 3 ROC curve depicting the association between natriuretic
peptide levels and survival. For interpretation see text(Table 2) and in terms of its relationship with Excess
ECFV (Tables 2 and 3). This is perhaps surprising as
ANP is released predominantly by atria and has much
shorter half-life compared to BNP, which is predomin-
antly released by the ventricle. This finding suggests that
cardiac function may be a major confounder for fluid
overload leading to excess ECF. It has been suggested
that ANP is more responsive to intravascular volume
changes in HD patients than BNP whilst BNP may beFig. 4 Mean % ECF excess post dialysis based on bioimpedance
estimates modified by UF volume. Euvolaemic = ideal ECF [Chamney
(25) +/− 5 %. Hypovolaemic = ECF < 95 % ideal. Hypervolaemic = ECF >
105 % ideal. Numbers in these categories indicate the percentage of the
study population with ECF values in that category
Table 5 Effect of ANP and BNP on survival in Cox Regression models of survival in 170 Haemodialysis patients
B SE Wald p-value Exp(B)
Model 1 Baseline +Log pre-dialysis ANP .204 .136 2.263 .132 1.227
Model 2 Baseline +Log post-dialysis ANP .235 .147 2.560 .110 1.265
Model 3 Baseline +Log BNP .261 .093 7.916 .005 1.299
The baseline model included age, sex, ethnicity, pre-dialysis weight, residual urea clearance > 1 ml/min, Charlson Comorbidity Index, serum albumin, and elevated
CRP (>5 mg/l). Log BNP was a significant determinant of survival in this model unlike Log pre-dialysis ANP and Log post-dialysis ANP
Sivalingam et al. BMC Nephrology  (2015) 16:218 Page 9 of 10more reflective of cardiac dysfunction [34]. Our findings
also raise the possibility of a dissociation between these
biomarkers in relation to fluid overload – with changes
in ANP being more reflective of acute volume change
and BNP more reflective of a chronically fluid over-
loaded state.
Bioimpedance analysis was used to classify patients in
the study to three groups based on their excess ECF,
both pre and post dialysis. Patients who were classified
as being fluid overloaded pre dialysis had significantly
higher levels of natriuretic peptides compared to euvo-
laemic and hypovolaemic subjects. These patients had
lower level of residual renal function compared to re-
mainder of the patients. In addition, their post dialysis
systolic blood pressure remained high despite the high
ultrafiltration rate. A significantly higher proportion of
patients (55 %) were classified as hypovolaemic post
dialysis, mirroring the proportion of hypervolaemic
group pre dialysis. Likewise, patients who were hypovol-
aemic tended to have lower post dialysis systolic blood
pressure and lower ultrafiltration rate. Intra dialytic
hypotension, a marker of hypovolaemia, has been in-
creasingly recognised as a marker of adverse outcomes
in HD patients. In addition to asymptomatic myocardial
ischaemia [35], it is also associated with other adverse
effects such as accelerated decline in residual renal
function [36] and increased risk of vascular access
thrombosis [37].
Patients on renal replacement therapy have high
risk of cardiovascular disease and fluid overload is a
major confounder for cardiac disease including left
ventricular dysfunction. In ROC analysis we found
that BNP was a stronger predictor of 5-year survival
in this cohort of patients compared to pre- and post-
dialysis ANP. We also found that BNP but not ANP
was an independent predictor of mortality in Cox re-
gression analysis in this group of patients. Several
studies have shown the relationship between BNP and
survival in HD patients and some have utilised NT
proBNP rather than BNP [3, 38–41]. BNP and NT
proBNP were compared in an earlier study and there
were only marginal differences between them with
regards to survival in HD patients [31]. None to our
knowledge has compared the contributions to survival
prediction of ANP and BNP in this setting.Conclusions
In conclusion bioimpedance analysis suggested that
ECFV expansion was present in over 50 % of patients
pre-dialysis though a significant proportion (21 %) had a
depleted ECFV in this setting. The situation was re-
versed post-dialysis. A raised JVP >3 cm was the most
reliable clinical sign of ECFV expansion inferred from
bioimpedance measurements and natriuretic peptide
levels. The vast majority of patients with this sign also
had lung crepitations or peripheral oedema or both. We
found BNP to be a stronger predictor of volume over-
load in this setting than pre- or post-dialysis ANP. BNP
was also a stronger predictor of survival over an
extended follow up period of 5 years. We found no clear
role for measurement of ANP levels in this setting,
though changes in ANP may be a strong indicator of
acute changes in volume status. Further work is neces-
sary to explore the possible role of monitoring these
levels of peptides in the management of volume status
and cardiovascular risk in HD patients.
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